1. bookVolume 1 (2017): Issue 3 (July 2017)
Journal Details
License
Format
Journal
eISSN
2564-615X
First Published
30 Jan 2017
Publication timeframe
4 times per year
Languages
English
Open Access

A potential therapeutic role in multiple sclerosis for stigmast-5,22-dien-3β-ol myristate isolated from Capparis ovata

Published Online: 20 Jul 2017
Volume & Issue: Volume 1 (2017) - Issue 3 (July 2017)
Page range: 241 - 246
Journal Details
License
Format
Journal
eISSN
2564-615X
First Published
30 Jan 2017
Publication timeframe
4 times per year
Languages
English
Abstract

Multiple sclerosis (MS) is an autoimmune disease of the human central nervous system. It is one of the most common neurological disorders around the world and there is still no complete cure for MS. Purification of a terpenoid from Capparis ovata was carried out and its structure was elucidated as stigmast-5,22-dien-3β-ol, myristate (3β,22E-stigmasteryl myristate; SDM) by NMR and mass spectral analyses. No information regarding its any health effect is available in the literature. In the present study, we have described its effects on inflammatory factors such as the expression levels of cytokines, chemokines and adhesion molecules as well as apoptosis/infiltration and myelination in SH-SY5Y cells. The expression levels of proinflammatory or inflammatory cytokines and chemokines such as NF-κB1, CCL5, CXCL9, CXCL10 and HIF1A along with T-cell activating cytokines such as IL-6 and TGFB1 were significantly downregulated with SDM treatment. Moreover, the expression levels of the main myelin proteins such as MBP, MAG and PLP that are essential for healthy myelin architecture were significantly up-regulated. The results presented in this study strongly suggest that the SDM offers a unique possibility to be used with autoimmune diseases, including MS due to its activity on the manipulation of cytokines and the promotion of myelin formation.

1. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol 2001; 2(9): 762-764.10.1038/ni0901-76211526378Open DOISearch in Google Scholar

2. Goldenberg MM. Multiple Sclerosis Review. Pharmacy and Therapeutics 2012; 37(3): 175-184.Search in Google Scholar

3. Sospedra M. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747.10.1146/annurev.immunol.23.021704.11570715771584Open DOISearch in Google Scholar

4. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nature Review Immunology 2015; 15(9): 545-558.10.1038/nri387126250739Search in Google Scholar

5. Aulchenko YS, Hoppenbrouwers IA, Ramagopalan SV, Broer L, Jafari N, Hillert J, Link J, Lundstrom W, Greiner E, DessaSadovnick A, Goossens D, Van Broeckhoven C, Del-Favero J, Ebers GC, Oostra BA, VanDuijn CM, Hintzen RQ. Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis’’, Nature Genetics 2008; 40(12): 1402-1403.Search in Google Scholar

6. Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV. An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis. PLoS one 2010; 5(9): e12496.10.1371/journal.pone.0012496293169620824132Search in Google Scholar

7. Yadav V, Shinto L, Bourdette D. Complementary and alternative medicine for the treatment of multiple sclerosis. Expert Rev Clin Immunol 2010; 6(3): 381-395.10.1586/eci.10.12290123620441425Open DOISearch in Google Scholar

8. Yadav V, Narayanaswami P. Complementary and alternative medical therapies in multiple sclerosis--the American Academy of Neurology guidelines: a commentary. Clin Ther 2014; 36(12): 1972-1978.10.1016/j.clinthera.2014.10.01125467189Search in Google Scholar

9. Davis PH. Flora of Turkey and the east Aegean islands. Edinburgh University Press 1965.Search in Google Scholar

10. Arslan R, Bektas N, Ozturk Y. Antinociceptive activity of methanol extract of fruits of Capparis ovata in mice. Journal of Ethnopharmacology 2010; 131(1): 28-32.10.1016/j.jep.2010.05.06020595018Search in Google Scholar

11. Tlili N, Trabelsi H, Renaud J, Khaldi A, Mayer PM, Triki S. Triacylglycerols and phospholipids composition of caper seeds (Capparis spinosa). Journal of the American Oil Chemists’ Society 2011; 88(11): 1787-1793.10.1007/s11746-011-1855-3Open DOISearch in Google Scholar

12. Panico AM, Cardile V, Garufi F, Puglia C, Bonina F, Ronsisvalle G. Protective effect of Capparis spinosa on chondrocytes. Life Sci 2005; 77(20): 2479-2488.10.1016/j.lfs.2004.12.05115946691Search in Google Scholar

13. Sen A, Topcu G, Ozgun O, Kolak U, Hacibekiroglu I, Celik G, Arslan S. Anti-neuroinflammatory effect of butanolic subextract of Capparis ovata water extract used as an alternative and complementary treatment for multiple sclerosis. Journal of Neuroimmunology 2014; 275: 172-173.10.1016/j.jneuroim.2014.08.464Search in Google Scholar

14. Ozgun- Acar O, Celik-Turgut G, Gazioglu I, Kolak U, Ozbal S, Ergur BU, Arslan S, Sen A, Topcu G. Capparis ovata treatment suppresses inflammatory cytokine expression and ameliorates experimental autoimmune encephalomyelitis model of multiple sclerosis in C57BL6 mice. Journal of Neuroimmunology 2016; 298: 106-116.10.1016/j.jneuroim.2016.07.010Search in Google Scholar

15. Torkildsen O, Myhr KM, Bo L. Disease-modifying treatments for multiple sclerosis - a review of approved medications. European Journal of Neurology 2016; 23(1): 18-27.10.1111/ene.12883Open DOISearch in Google Scholar

16. Brochet B, Guinot P, Orgogozo JM, Ginkgolide Study Group in Multiple Sclerosis. Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. Journal of Neurology1995; 58: 360-362.10.1136/jnnp.58.3.360Search in Google Scholar

17. Pertwee RG. Cannabinoids and multiple sclerosis. Pharmacology & Therapeutics 2002; 95(2): 165-174.10.1016/S0163-7258(02)00255-3Search in Google Scholar

18. Lovera J, Bagert B, Smoot K, Morris CD, Frank R, Bogardus K, Wild K, Oken B, Whitham R, Bourdette D. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. MultScler 2007; 13(3): 376-85.10.1177/135245850607121317439907Search in Google Scholar

19. Keating GM. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity. Drugs 2017; 77(5): 563-574.10.1007/s40265-017-0720-628293911Search in Google Scholar

20. Gabay O, Sanchez C, Salvat C, Chevy F, Breton M, Nourissat G, Wolf C, Jacques C, Berenbaum F. Stigmasterol: a phytosterol with potential anti-osteoarthritic properties. Osteoarthritis and Cartilage 2010; 18(1): 106-116.10.1016/j.joca.2009.08.01919786147Open DOISearch in Google Scholar

21. Tajouri L, Fernandez F, Griffiths LR. (). Gene Expression Studies in Multiple Sclerosis. Current Genomics 2007; 8(3): 181-189.10.2174/138920207780833829243535218645602Search in Google Scholar

22. Bartosik-Psujek H, Stelmasiak Z. The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. Eur J Neurol 2005; 12(1): 49-54.10.1111/j.1468-1331.2004.00951.x15613147Search in Google Scholar

23. Galimberti D, Scalabrini D, Fenoglio C, Comi C, De Riz M, Venturelli E, Lovati C, Mariani C, Monaco F, Bresolin N, Scarpini E. CXCL10 haplotypes and multiple sclerosis: association and correlation with clinical course. Eur J Neurol 2007; 14(2): 162-167.10.1111/j.1468-1331.2006.01629.x17250724Search in Google Scholar

24. Le Moan N, Baeten KM, Rafalski VA, KyuRyu J, RiosCoronado PE, Bedard C, Akassoglou K. HypoxiaInducible Factor-1α in Astrocytes and/or Myeloid Cells Is Not Required for the Development of Autoimmune Demyelinating Disease. E Neuro 2015; 2(2): 1-12.Search in Google Scholar

25. Miterski B, Bohringer S, Klein W, Sindern E, Haupts M, Schimrigkand S, Epplen JT. Inhibitors in the NFκB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations. Genes and Immunity 2002: 3, 211-219.10.1038/sj.gene.636384612058256Open DOISearch in Google Scholar

26. Podbielska M, Banik NL, Kurowska E, Hogan EL. Myelin Recovery in Multiple Sclerosis: The Challenge of Remyelination. Brain Sciences 2013; 3(3): 1282-1324.10.3390/brainsci3031282406187724961530Open DOISearch in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo